- Home
- VLGEA vs FULC Comparison
VLGEA vs FULC Comparison
Compare VLGEA & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VLGEA | FULC |
|---|---|---|
| Founded | 1937 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Food Chains | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 480.8M | 468.1M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | VLGEA | FULC |
|---|---|---|
| Price | $35.08 | $9.08 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $12.71 |
| AVG Volume (30 Days) | 41.2K | ★ 827.5K |
| Earning Date | 12-02-2025 | 10-29-2025 |
| Dividend Yield | ★ 2.86% | N/A |
| EPS Growth | ★ 4.59 | N/A |
| EPS | ★ 3.75 | N/A |
| Revenue | ★ $2,345,586,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $9.61 | ★ N/A |
| Revenue Growth | 3.88 | ★ 2752.05 |
| 52 Week Low | $29.64 | $2.32 |
| 52 Week High | $40.15 | $12.19 |
Technical Indicators
Market Signals| Indicator | VLGEA | FULC |
|---|---|---|
| Relative Strength Index (RSI) | 54.66 | 44.04 |
| Support Level | $34.26 | $10.75 |
| Resistance Level | $36.05 | $12.05 |
| Average True Range (ATR) | 0.86 | 0.94 |
| MACD | 0.13 | -0.24 |
| Stochastic Oscillator | 48.09 | 11.80 |
Price Performance
Historical ComparisonAbout VLGEA Village Super Market Inc.
Village Super Market Inc operates a chain of ShopRite supermarkets, a few of which are in northern New Jersey, southern New Jersey, Maryland, and in northeastern Pennsylvania. The company is a member of Wakefern Food Corporation (Wakefern), a retailer-owned food cooperative and owner of the ShopRite name. It consists of one operating segment, the retail sale of food and nonfood products.
About FULC Fulcrum Therapeutics Inc.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.